This funding round was led by Bain Capital Life Sciences and SV Health Investors. They join existing investors, including Bill Gates and Access Biotechnology. The money will be used to support several clinical trials.
Join us September 28 at Pegasus Park in Dallas to meet select Employee Benefits Startups, over 30 investors, and to be a part of the thought provoking discussions around mental health, pharmacy benefits, the cost of healthcare and reaching consumers.
Hurry the offer to save $100 ends Friday Sept 16th.
By Katie Adams Tuesday, September 13, 2022 6:55 PM
Violence is common and increasing across California, according to new research. Despite this trend, the report said statewide violence prevention programs are ill-funded and treated as a non-priority. It advocated for more policy that addresses the root causes of violence by improving the financial, social and emotional security of vulnerable populations.
By Frank Vinluan Tuesday, September 13, 2022 6:53 PM
Rubius Therapeutics is laying off about 75% of its workforce in a restructuring that spells the end of its red blood cell therapies in early clinical development for cancer. The biotech is turning its focus to a new platform for making cell therapies that it says offers key advantages over its current technology.
By Katie Adams Tuesday, September 13, 2022 2:28 PM
Novome Biotechnologies — a biotech that CEO Blake Wise says is only company to pursue engineered cell therapy with microbes for the treatment of chronic diseases — raised $43.5 million in Series B funds. The biotech will use the money to advance clinical testing for its lead drug candidate, which seeks to decrease patients' urinary oxalate, as well as advance its pipeline of preclinical genetically engineered microbes.
By Stacey Rivkin Tuesday, September 13, 2022 2:00 PM
Gen Z is the most diverse, digitally-proficient generation yet. Gen Z MSLs have the skills and power to change the future of healthcare by using technology to redefine who KOLs are, how they are engaged, and ultimately, how clinical trials are run – and with it the potential to make health equity a reality.
By Frank Vinluan Tuesday, September 13, 2022 12:20 PM
Akero Therapeutics' experimental NASH drug, efruxifermin, met the main and secondary goals of Phase 2b clinical trial. The biotech will still need to show that the drug's efficacy can hold up in a pivotal study, but the results so far are a positive sign for the NASH field, which has been marred by clinical trial failures.
By Dr. Robert Mirsky Tuesday, September 13, 2022 8:15 AM
Before we can consider telehealth as part of ongoing, longitudinal healthcare, there are major issues that need to be addressed, including integration with traditional healthcare services, and inequities among patient subgroups that arise out of economic, infrastructure, and technological barriers.
Today, the pharmaceutical industry is undergoing a rapid and dynamic transformation. Successful contract management plays an instrumental role in navigating this landscape.
No comments